We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

One of the two CD cases with remaining enteropathy on a GFD that were misclassified based on anti-TG2 (see Clinical antibody tests) showed a level of the TNFRSF9 mRNA marker for normalized CD ...

It is designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of ...

Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

It is designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of normal ...

On 1/24/25, Gladstone Land Corp's 6.00% Series C Cumulative Redeemable Preferred Stock (Symbol: LANDP) will trade ex-dividend, for its monthly dividend of $0.125, payable on 1/31/25. As a ...

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for ...

It is designed to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of ...